Clinical update


Jeroen J. Bax1*, Victoria Delgado1, Vinayak Bapat2, Helmut Baumgartner3, Jean P. Collet4, Raimund Erbel5, Christian Hamm6, Arie P. Kappetein7, Jonathon Leipsic8, Martin B. Leon9, Philip MacCarthy10, Nicolo Piazza11,12, Philippe Pibarot13, William C. Roberts14, Josep Rodés-Cabau15, Patrick W. Serruys7, Martyn Thomas2, Alec Vahanian16, John Webb8, Jose Luis Zamorano17, and Stephan Windecker18

1Department of Cardiology, Leiden University Medical Center, Albinusdreef 2 2300 RC, Leiden, The Netherlands; 2Department of Cardiology and Cardiothoracic Surgery, St Thomas' Hospital, London, UK; 3Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany; 4Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere, Paris, France; 5Department of Cardiology, West-German Heart Center Essen, University Duisburg Essen, Essen, Germany; 6Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany; 7Erasmus Medical Center, Rotterdam, The Netherlands; 8St Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada; 9Columbia University Medical Center, Center for Interventional Vascular Therapy, New York Presbyterian Hospital, New York, USA; 10Cardiovascular Department, King’s College Hospital, London, UK; 11Interventional Cardiology, McGill University Health Center, Montreal, Canada; 12Cardiovascular Surgery, German Heart Center Munich, Bavaria, Germany; 13Quebec Heart and Lung Institute, Quebec, Canada; 14Baylor Heart and Vascular Institute and the Departments of Internal Medicine (Division of Cardiology) and Pathology, Baylor University Medical Center, Dallas, TX, USA; 15Department of Cardiology, Laval University, Quebec, Canada; 16Bichat Hospital, University Paris VII, Paris, France; 17Cardiac Imaging Department, University Hospital Ramon y Cajal, Madrid, Spain; and 18Department of Cardiology, Bern University Hospital, Bern, Switzerland

Received 16 April 2014; revised 13 May 2014; accepted 2 June 2014; online publish-ahead-of-print 25 July 2014

An exponential increase in the use of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis has been witnessed over the recent years. The current article reviews different areas of uncertainty related to patient selection. The use and limitations of risk scores are addressed, followed by an extensive discussion on the value of three-dimensional imaging for prosthesis sizing and the assessment of complex valve anatomy such as degenerated bicuspid valves. The uncertainty about valvular stenosis severity in patients with a mismatch between the transvalvular gradient and the aortic valve area, and how integrated use of echocardiography and computed tomographic imaging may help, is also addressed. Finally, patients referred for TAVI may have concomitant mitral regurgitation and/or coronary artery disease and the management of these patients is discussed.

Keywords Transcatheter aortic valve implantation • Aortic stenosis • Imaging • Patient selection • Mitral regurgitation • Coronary artery disease

Introduction

In 2002, transcatheter aortic valve implantation (TAVI) was introduced as an alternative treatment in patients with severe aortic valve stenosis (AS). Since then several transcatheter valve prostheses have received CE approval including the balloon-expandable Edwards SAPIEN valve prostheses (Edwards SAPIEN; Edwards Lifesciences, Irvine, CA, USA) and its recent device iterations (SAPIEN XT, SAPIEN 3) available for transfemoral and transapical access, the self-expandable CoreValve system (Medtronic, Inc., Minneapolis, MN, USA), the transfemoral...
self-expanding Portico valve (St Jude Medical, St Paul, MN, USA), the Direct Flow prosthesis (Direct Flow Medical, Inc., Santa Rosa, CA, USA), the Lotus valve (Boston Scientific Corporation, Natick, MA, USA), and the transapical Symetic Acurate (Symetis SA, Ecublens, Switzerland), JenaValve (JenaValve, Munich, Germany), and Medtronic Engager (Medtronic, Inc., Minneapolis, MN, USA). Over the years, a rapid development in prosthetic valves has been witnessed, with the introduction of various prosthetic designs and sizes. The crossing profile of the delivery sheaths has been improved and the sizes have been reduced. These developments have significantly improved procedural success rates and outcome, with a reduction in complications.

It is estimated that >100 000 TAVIs have been performed between 2002 and 2013. It has also become evident that many areas of uncertainty exist around TAVI, which are addressed in the current reviews. In the first part, issues around patient selection are discussed, such as the need for improved risk scores, and the value of sophisticated, three-dimensional non-invasive imaging for prosthesis sizing. Uncertainty also exists on optimal visualization of native valve anatomy in bicuspid valves, and the quantification of stenosis severity in low-flow low-gradient AS. Another issue of controversy is the outcome after TAVI in patients with pre-existent left ventricular (LV) dysfunction. Finally, concomitant mitral regurgitation (MR) and coronary artery disease (CAD) are frequently encountered and the need and timing for therapeutic intervention is unclear as well as their impact on prognosis.

The available literature on these issues will be reviewed and the specific areas, where conclusive data are lacking will be summarized. Part 2 will focus on procedural issues and outcomes.

Risk scores for patient

The decision of surgical aortic valve replacement (SAVR) or TAVI in symptomatic severe AS depends on the presence of contraindications for SAVR or a high-surgical risk. Two risk scores are used to calculate the risk of cardiac surgery (including SAVR): the Society of Thoracic Surgeons-Predicted Risk of Mortality score (STS-PROM) and the European System for Cardiac Operative Risk Evaluation (EuroSCORE) model (additive and logistic). When the STS-PROM score exceeds 10% or when the logistic EuroSCORE is ≥20%, referral for TAVI should be considered. These risk scores, however, were developed and validated in the standard surgical risk populations and predict short-term mortality (hospital or 30-day) after cardiac surgery. Both scoring systems have, therefore, important deficiencies especially in a heterogeneous high-risk patient population such as TAVI candidates. Moreover, they are inadequate to predict the long-term outcome or procedural complications. The EuroSCORE II has recently been developed from data of 22 381 patients undergoing cardiac surgery and validated in a subset of 5553 patients. Variables such as impaired mobility, New York Heart Association (NYHA) functional class and diabetes were incorporated into the new risk score. This score appears to have superior discriminatory power for predicting 30-day mortality over the original logistic EuroSCORE.

The reasons for suboptimal performance of the scores are diverse. The development cohort of patients from whom a score was derived is usually very different from the patients to whom it is applied. Also, changes in surgical techniques, peri-operative care, patients’ characteristics, and differences in hospitals and even surgeons or interventionists may further explain the modest performance of the scores. Finally, risk scores are usually developed through the standard statistical approaches, not taking into account risk factor interactions or procedure-specific weightings.

The application of risk scores for referral to TAVI is also limited, since conventional cardiovascular risk factors (i.e., peripheral vascular disease, diabetes) are included in the scores, but specific risk factors for TAVI are not included, such as frailty, porcelain aorta, vessel tortuosity, chest wall malformation, or chest radiation. In addition, risk predictions should be based on standardized definitions such as the Valve Academic Research Consortium (VARC) criteria.

The EuroSCORE II showed better discriminatory power for predicting 30-day mortality after TAVI, when compared with the logistic EuroSCORE and STS-PROM in a cohort of 350 TAVI patients (areas under the curve 0.70, 0.61, and 0.59, respectively). Recently, based on data from the FRANCE-2 registry, a risk score has been proposed which includes a specific procedural variable in the calculation: the TAVI access site (transfemoral vs. non-transfemoral). However, the discrimination of this risk score was still modest (area under the curve 0.59), indicating the limitations of the score to reliably individualize risk.

Accordingly, the unmet needs currently include improvements in risk scores to better individualize patient risk in the populations considered for TAVI. The open questions are (i) how to improve discrimination between low- and high-surgical risk (including SAVR), (ii) how to identify patients who should be referred for TAVI, and (iii) how to predict procedural risk and outcome in TAVI candidates.

It may be difficult (if not impossible) to develop the specific scores that answer these questions, since this concerns a complex patient group, in whom individualized decision-making may be preferred to ensure that every patient receives the optimal therapy. In addition to scores, discussion on individual patient management should take place in the ‘Heart Team’ including cardiologists with specific interest on valvular heart disease, transcatheter interventions and cardiac imaging, cardiothoracic surgeons, anaesthesiologists, and other specialists such as geriatricians.

Imaging to guide prosthesis sizing

Aortic valve annulus sizing is crucial for accurate selection of prosthesis size. Three-dimensional imaging modalities are superior to two-dimensional (2D) techniques to assess the elliptical geometry and to accurately measure the dimensions of the aortic annulus. Compared with 2D TEE, 3D imaging modalities may modify sizing in up to 40% of patients.

In daily clinical practice, the technique of choice for aortic annulus sizing is multi-detector row computed tomography (MDCT) which provides high spatial resolution data that can be easily post-processed using dedicated TAVI workstation packages. Magnetic resonance imaging provides an alternative technique for aortic annulus sizing, but is infrequently used in clinical practice. During the procedure, 3D TEE can also be used for aortic annulus sizing, and current ultrasound systems include dedicated platforms that permit live measurements of 3D data. From 3D TEE and MDCT different measurements can be derived which have been associated with paravalvular aortic regurgitation (AR) (Table 1 and Figure 1).
Selection of prosthesis size based only on minimum or maximum diameters may result in both significant under- and oversizing, respectively, due to their inability to characterize the non-circular geometry of the annulus. The consequences of an undersized prosthesis include significant paravalvular AR or increased risk of prosthesis migration while an oversized prosthesis increases the risk of annulus rupture. Subsequent studies have used the perimeter or area measurements to reduce the risk of these complications.

Wilson et al. showed that the difference between the MDCT perimeter or area measurements and the nominal prosthesis perimeter or area, predicted the presence of significant paravalvular AR (area under curve 0.80 and 0.71, respectively). Implantation of a prosthesis with a nominal area < 10% greater than the MDCT annulus area was associated with an increased risk of significant paravalvular AR. In contrast, a relative oversizing ≥ 20% was associated with an increased risk of aortic annulus rupture. Recently, a prospective study recommended between 5 and 10% of prosthesis oversizing (nominal prosthesis area/MDCT annulus area) for Edwards SAPIEN valves to ensure appropriate apposition of the prosthetic frame into the aortic annulus and maximize annular sealing by the prosthesis. If > 15–20% of oversizing was anticipated, intentional underexpansion of the selected prosthesis was recommended by underfilling the balloon 10% in order to minimize the risk of annulus rupture (Table 2). Of importance, prosthesis oversizing...
Based on diameter or perimeter is not equivalent to prosthesis oversizing based on the area: a 10–20% oversizing based on perimeter may correspond to 30–40% oversizing based on the area with consequent increased risk of annulus rupture. Similarly, several studies have shown that aortic annulus sizing with 3D TEE reduced the incidence of paravalvular AR after TAVI when compared with 2D TEE measurements.\textsuperscript{15,21,25} The main advantages of 3D TEE are that it can be performed during the procedure and does not involve radiation or ionized contrast agents which may impact on the renal function. However, this technique is operator dependent which may lead to some variability in aortic annulus sizing.

While advanced 3D imaging modalities have allowed for a better understanding of annulus geometry and sizing, the optimal measurement for sizing and degree of annulus oversizing by perimeter or area to reduce paravalvular AR while minimizing the risks of annular rupture remain still debated. Of note, sizing of valve prosthesis based on diameter or perimeter is not equivalent to prosthesis oversizing based on the area: a 10–20% oversizing based on perimeter may correspond to 30–40% oversizing based on the area with consequent increased risk of annulus rupture. Similarly, several studies have shown that aortic annulus sizing with 3D TEE reduced the incidence of paravalvular AR after TAVI when compared with 2D TEE measurements.\textsuperscript{15,21,25} The main advantages of 3D TEE are that it can be performed during the procedure and does not involve radiation or ionized contrast agents which may impact on the renal function. However, this technique is operator dependent which may lead to some variability in aortic annulus sizing.

### Table 2  Proposed sizing chart for the Edwards SAPIEN valve and the CoreValve system based on multi-detector row computed tomography measurements

<table>
<thead>
<tr>
<th></th>
<th>Edwards SAPIEN/SAPIEN XT prosthesis size</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diameter (mean), mm</td>
<td>20-mm</td>
<td>23-mm</td>
<td>26-mm</td>
</tr>
<tr>
<td></td>
<td>Area, cm(^2)</td>
<td>2.41–3.20(^a)</td>
<td>3.20–4.15(^b)</td>
<td>4.15–5.30(^c)</td>
</tr>
<tr>
<td></td>
<td>Perimeter, mm</td>
<td>55.6–65.4</td>
<td>65.4–75.2</td>
<td>75.2–85.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Edwards SAPIEN 3</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Area, cm(^2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Area-derived diameter, mm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diameter (mean), mm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Area, cm(^2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perimeter, mm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>3.38–4.30</td>
<td>4.30–5.46</td>
<td>5.40–6.80</td>
</tr>
<tr>
<td></td>
<td>—</td>
<td>20.7–23.4</td>
<td>23.4–26.4</td>
<td>26.2–29.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>CoreValve system</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diameter (mean), mm</td>
<td>18–20</td>
<td>20–23</td>
</tr>
<tr>
<td></td>
<td>Area, cm(^2)</td>
<td>2.54–3.14</td>
<td>3.14–4.15</td>
</tr>
<tr>
<td></td>
<td>Perimeter, mm</td>
<td>56.3–62.8</td>
<td>62.8–72.3</td>
</tr>
</tbody>
</table>

\(^a\)Consider balloon underfilling from 2.4 to 2.7 cm\(^2\).

\(^b\)Consider balloon underfilling from 3.20 to 3.50 cm\(^2\).

\(^c\)Consider balloon underfilling from 4.20 to 4.45 cm\(^2\).

\(^d\)Consider balloon underfilling from 5.35 to 5.60 cm\(^2\).

**Bicuspid aortic valve: prevalence, diagnosis, and implications for transcatheter aortic valve implantation**

It has been estimated that 1% of the worldwide population has a congenitally bicuspid aortic valve (BAV). A recent necropsy study of 218 unoperated patients >20 years of age with congenitally malformed aortic valves (unicuspid or bicuspid) showed that the valve had functioned abnormally in 75% of patients, with AS being the most frequent dysfunction (87%).\textsuperscript{26} The frequency of the operatively-excised stenotic unicuspid and BAVs has also been studied (Figure 2). Among 219 men aged 71–80 years who underwent SAVR between 1993 and 2004 at a single centre, there were 4 unicuspid, 94 bicuspid and 119 tricuspid valves, whereas of the 138 women aged 71–80 years there were 1 unicuspid, 55 bicuspid, and 79 tricuspid valves.\textsuperscript{27} Interestingly, in 1.4% of patients the anatomy of the aortic valve could not be determined.

Diagnosis of bicuspid anatomy with 2D echocardiography can be challenging. In 100 patients (mean age 70 years) with isolated AS who underwent SAVR, the prevalence of congenitally malformed valves was 51% and in 14 patients, 2D echocardiography could not diagnose the anatomy of the aortic valve [with 10 (71%) having congenitally malformed valves].\textsuperscript{28} Magnetic resonance imaging and MDCT provide a higher spatial resolution data and have demonstrated improved accuracy to identify BAV.\textsuperscript{29,30} In 50 patients with AS (34% BAV) undergoing SAVR, the accuracy of MDCT to diagnose the aortic valve anatomy was superior to 2D echocardiography (98 vs. 66%, respectively).\textsuperscript{30} This may be related to the better visualization of the valvular pathology despite the presence of heavy calcifications as observed in operatively excised bicuspid stenotic valves.\textsuperscript{31} Based on this evidence, there may be a significant proportion of patients with severely stenotic BAV who could be candidates for TAVI. However, BAV has been considered a less favourable...
anatomy for transcatheter valve deployment and function and accordingly several trials, including the Placement of AoRTic TraNs-catheterER valves (PARTNER) trials, have excluded patients with this anatomy.32,33 Recently, published series have demonstrated that TAVI is a feasible and safe procedure in patients with severe AS and BAV.34–36 In the USA, Transcatheter Valve Therapy registry, 2% of the patients had BAVs.37 Among 229 patients undergoing pre-procedural MDCT, 9.2% patients had a BAV.38 Compared with patients with tricuspid aortic valves, the CoreValve system was more frequently used among patients with BAV (47.6 vs. 16.3%, P = 0.002). The procedural outcomes were comparable between patients with BAV and patients with tricuspid valves in terms of successful implantation (100 vs. 93%, P = 0.37), significant AR after TAVI (19 vs. 14.9%, P = 0.54) and 30-day combined safety endpoint (14.3 vs. 13.5%, P = 1.00).34 Extent and amount of valve calcifications may also impact on the deployment of the transcatheter valves (Figure 3). Wijesinghe et al.34 reported a circular deployment of the prosthesis in 11 patients with stenotic BAV undergoing TAVI with the Edwards SAPIEN valve, whereas others reported an elliptical deployment in 36 patients with stenotic BAV treated with the CoreValve system.34,35 An elliptical deployment of the transcatheter valve may lead to valve dysfunction and significant paravalvular AR.

Finally, it is important to note that BAV anatomy may be associated with aortopathy (aneurysm of the ascending aorta or aortic coarctation) that should be evaluated prior to TAVI, since it is a contraindication.35,38 In addition, left coronary artery dominance is more frequently observed among patients with BAV. The height and location of the coronary ostia may also be different in these patients and accurate assessment is crucial to anticipate potential complications such as coronary ostium occlusion by a bulky calcified cusp. Multi-detector row computed tomography may be an accurate and comprehensive imaging tool to select patients with severely stenosed BAV who are considered for TAVI.

Low-flow, low-gradient aortic stenosis: how to assess severity

The assessment of severity is an important step in the management of patients with AS. The clinical utility of measuring stenosis severity is three-fold: to ensure that AS is the cause of symptoms, to evaluate the prognosis, and to decide upon treatment.

Echocardiography is the reference method for evaluating AS severity, but accurate assessment is sometimes challenging. Severe AS with small AVA (<1.0 cm²) and low transvalvular gradients is not uncommon in daily clinical practice. According to recent guidelines, severe AS is defined as an aortic valve area (AVA) <1 cm², a mean gradient >40 mmHg and maximum jet velocity >4 m/s.6,7 However, many patients have discordant findings, mostly with small AVA, but with small gradients. In the PARTNER trials, with centralized echocardiographic evaluation of 951 patients with severe AS, 45% had a low transvalvular gradient.39 This situation raises uncertainty as regard the severity of AS as well as the indication for intervention.

The entity of severe AS with a low transvalvular gradient has first been recognized in patients with reduced LV ejection fraction (LVEF).40 In the PARTNER trials, 15% of patients with low LVEF had low-flow, low-gradient AS.39 In such patients, a small valve area does not definitely confirm severe AS, since mild to moderately diseased valves may not open fully (secondary to the reduced LV function), resulting in a small valve area (pseudo-severe AS) which is not an indication for intervention. Low-dose dobutamine stress echocardiography may be helpful to distinguish severe AS from pseudo-severe AS. In severe AS, the valve area changes minimally during low-dose dobutamine echocardiography, but the gradient increases significantly (mean gradient >40 mmHg) (Figure 4 and Supplementary material online, Movie S1).
More recently, the possibility of severe AS in patients with AVA <1.0 cm² and a mean gradient <40 mmHg, despite preserved LVEF, has been suggested, introducing the new entity of paradoxical low-flow (stroke volume index \( \leq 35 \text{ mL/m}^2 \)), low-gradient AS. In the PARTNER trials, 14% of the AS patients had normal LVEF, low-flow, and low-gradient. The management of this subset of AS patients remains challenging.

When confronted with this entity the following steps should be taken: first, potential errors in the measurement of gradient, stroke volume index, AVA should be excluded. Secondly, to eliminate the confounding effect of small body size, calculation of the indexed AVA may be helpful. A value \( >0.6 \text{ cm}^2/\text{m}^2 \) indicates moderate AS. Finally, establishing whether the global haemodynamic load is severely increased (i.e. valvulo-arterial impedance) may be of help.

Corroborating methods are useful in cases where echocardiography is technically challenging or inconclusive because of discordant evaluation of severity. Particular attention has recently been given to the evaluation of the degree of valve calcification. Recent studies have emphasized the use of MDCT for the quantification of valvular calcification (Figure 5). Aortic valve calcification load identifies severe AS accurately (sensitivity 86%, specificity >79%) in men (calcium score threshold \( \geq 2065 \text{ a.u.} \)) and in women (threshold \( \geq 1275 \text{ a.u.} \)). Clavel et al. applied these criteria to low-flow, low-gradient AS, and showed that at least half of the patients had severe AS irrespective of flow. Multi-detector row computed tomography has the advantage of being a reproducible technique which is flow-independent. Currently, MDCT and low-dose dobutamine echocardiography should not be considered as competitive but rather as complementary techniques (Figure 6).

Further studies comparing diagnostic strategies and outcome in patients with low-flow, low-gradient AS are needed to optimally identify and manage these patients. Alternatively, in patients in whom it is difficult to determine the precise AS severity, a symptomatic improvement after balloon valvuloplasty suggests the presence of a severe AS, and TAVI can be beneficial.

**Left ventricular systolic dysfunction and outcome**

The prevalence of LV systolic dysfunction among patients with severe AS treated with TAVI ranges between 6 and 11%, considering a cut-off value of LVEF \( \leq 30\% \), and between 27 and 46%, if LVEF is between 30 and 50%. Left ventricular ejection fraction is an important prognostic factor and is included in current operative risk scores. However, the association between LV systolic dysfunction and TAVI procedural risks remains controversial. While some studies have shown an increased procedural risk among
patients with low LVEF, other series have not confirmed this association. For example, in the Italian registry including 663 patients undergoing TAVI with the CoreValve system LVEF <40% was independently associated with early mortality. In contrast, data from the Pilot European Sentinel registry, including 4571 patients with 5.7% having an LVEF, did not demonstrate this association. Furthermore, it has been suggested that LVEF may not reflect the extent of myocardial dysfunction in patients with severe AS and concentric LV hypertrophy, whereas stroke volume may be a more comprehensive parameter of the effects of increased afterload on the LV. The recent subanalysis of the PARTNER trial including all cohorts showed that only low-flow (stroke volume index ≤35 mL/m²) was independently associated with 2-year mortality, whereas low-gradient and low LVEF were not associated.

**Figure 5**  Aortic valve calcification assessment. Calcium scoring using multi-detector row computed tomography. This figure shows three different patients with mild, moderate, or severe aortic valve calcification. The units used are arbitrary units (courtesy of Dr David Messika-Zeitoun). AVC, aortic valve calcification; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

**Figure 6**  Evaluation of patients with low-flow, low-gradient severe aortic stenosis. AS, aortic stenosis; AU, arbitrary units; AVA, aortic valve area; LV, left ventricular; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MDCT, multi-detector row computed tomography.
Importantly, TAVI has also been associated with significant improvement in LVEF at follow-up.\textsuperscript{54–59} The majority of series has shown a significant improvement in LVEF early after TAVI (before hospital discharge) which is generally followed by a gradual and sustained improvement at the 1-year follow-up.\textsuperscript{54,55,57–59} This improvement in LVEF is associated with a significant and durable improvement in symptoms, functional class and quality of life.\textsuperscript{33,48,58,60}

The degree of LVEF improvement is highly variable and depends on several factors. Compared with SAVR, LVEF improves more after TAVI.\textsuperscript{55,57} In the randomized PARTNER cohort A trial, LVEF improved earlier with TAVI, although there was no difference between groups at 2 years.\textsuperscript{49} It has been suggested that a greater improvement in LV function might be expected with TAVI since this is a less invasive procedure that may minimize myocardial injury and transcatheter aortic valves have superior haemodynamic performance.\textsuperscript{61} Other factors associated with changes in LVEF after TAVI include a lower mean aortic valve gradient and a higher baseline LVEF, previous permanent pacemaker, new-onset of a left bundle branch block and pacemaker implantation after TAVI.\textsuperscript{62,63} Transcatheter aortic valve implantation access (transfemoral vs. transapical) has been also associated with LVEF improvement in univariate analysis. Elmariah et al.\textsuperscript{56} showed that transfemoral access was an unadjusted predictor of LVEF improvement, whereas transapical access was not.

Based on this evidence, it seems that TAVI can be performed in patients with LV dysfunction with a modest risk and is associated with marked symptomatic and survival benefit. Important questions for the future include: How can we reduce the risk of TAVI in patients with severe LV dysfunction (LVEF < 20%)? How can we predict whether LV function will improve?

**Concomitant mitral regurgitation: prevalence, pathophysiology, and impact on outcome**

Mild MR is very common in patients with severe AS, being reported in 60–90%, but has in general raised little concern.\textsuperscript{54} However, even moderate MR has been reported in up to 74%\textsuperscript{55} although other authors reported only 13–17%.\textsuperscript{66,67} This variation may be (partially) due to differences in the methodology of MR grading. The high driving pressure in severe AS may easily lead to overestimation of MR severity when using colour flow mapping. Nevertheless, it has to be recognized that the study reporting the highest prevalence used vena contracta width—a less pressure-dependent measure of MR severity—for quantification.\textsuperscript{65} Reported prevalence of moderate or severe MR in patients eventually undergoing TAVI ranged between 19 and 33% (Figure 7).\textsuperscript{33,37,68–72}

**Aetiology and pathophysiology**

Concomitant MR may have different aetiologies which can have major impact on the response to aortic valve replacement and long-term outcome. Mitral regurgitation is considered functional (secondary MR) in the absence of structural pathology of the mitral valve. In patients with additional CAD, cardiomyopathy or atrial fibrillation with left atrial enlargement, and annulus dilation, functional MR may not only be a consequence of AS but may also relate to such concomitant cardiac disease. Annulus calcification is frequently present and it is difficult to decide how much it contributes to the presence of MR and whether to consider MR functional or at least partially structural. Less common, ‘degenerative MR’ (prolapse/flail) may co-exist as well as post-rheumatic MR or MR after infective endocarditis. Hekimian et al.\textsuperscript{73} reported in 187 patients referred for TAVI that 32% had functional and 68% organic MR. Figure 8 summarizes pathophysiological considerations.\textsuperscript{64} Left ventricular remodelling and increase in LV pressure caused by AS may generate MR or aggravate co-existing MR of other causes. Mitral regurgitation by itself or by promotion of atrial fibration may decrease functional capacity. On the other hand, MR can precipitate diagnostic challenges by reducing forward stroke volume resulting in low-flow, low-gradient AS, or by impeding detection of subclinical myocardial dysfunction due to relative increase in LVEF.\textsuperscript{64}

**Improvement of mitral regurgitation after transcatheter aortic valve implantation**

In 451 patients undergoing TAVI with balloon-expandable Edwards SAPIEN prostheses, 319 had mild or no MR, 89 had moderate, and 43 severe MR.\textsuperscript{71} One year after TAVI, among patients with moderate MR at baseline, 58% improved ≥ 1 grade, 17% remained unchanged and 1% worsened to severe while the remaining 24% of patients had died. Among patients with severe MR at baseline, 49% improved ≥ 1 grade and 16% remained unchanged at the 1-year follow-up (35% had died). Data from the PARTNER trial cohort A indicated no difference in MR improvement following TAVI vs. SAVR.\textsuperscript{19}

Varying results have been reported for the CoreValve system. In 58 patients undergoing TAVI with this device (16 with ≥ mild MR), De Chiara et al.\textsuperscript{74} found no change in MR in 55%, reduction in 12%, and worsening in 33% of their study population. Similarly, among 79 patients treated with the CoreValve system, Tzikas et al.\textsuperscript{72} reported improvement in MR severity in 25%, but worsening in 22% and new MR in 42%. Worsening of MR was suspected to be
related to deep implantation of the prosthesis in the LV outflow tract.\textsuperscript{72} Recent data from the CoreValve Italian registry ($n = 1007$ patients, $337$ with $\geq$ moderate MR) showed similar results as those with the Edwards SAPIEN valve: moderate MR improved in 35\% and severe MR in 47\%.\textsuperscript{68}

Improvement of MR can be observed early and late after successful AS intervention (Figure 9). Possible mechanisms for the improvement of MR after successful AS intervention are the decrease in LV pressure overload and LV—left atrium gradient but also LV reverse remodelling due to afterload reduction and relieve of (intermittent) ischaemia after revascularization. While improvement caused by LV—left atrium gradient reduction is supposed to occur early, improvement due to LV reverse remodelling should take more time. Interestingly, most improvement in MR was observed within 7 days early after TAVI,\textsuperscript{73} with little change between Day 7 and 1 month after TAVI, although LV reverse remodelling was observed at 1 month. Similarly, in the PARTNER trial MR predominantly improved acutely after TAVI.\textsuperscript{49}

How to predict improvement in MR after TAVI remains challenging. In patients undergoing TAVI, the baseline mean transvalvular gradient $\geq 40$ mmHg, functional MR, the absence of pulmonary hypertension, and the absence of atrial fibrillation were independently associated with improvement in MR at 1 year.\textsuperscript{21} In addition, improvement in MR after balloon valvuloplasty as bridge to TAVI in patients with severe AS and very high risk could suggest a sustained reduction in MR after TAVI.\textsuperscript{75}

\textbf{Impact of mitral regurgitation on outcome after transcatheter aortic valve implantation}

After TAVI, patients with moderate or severe MR were reported to have a higher 30-day mortality but similar survival after 1 month.\textsuperscript{71} D’Onofrio et al.\textsuperscript{76} found a trend towards higher hospital mortality in patients with more than mild MR. Hutter et al.\textsuperscript{69} could not identify moderate or severe MR as an independent predictor of mortality while in the CoreValve Italian registry 30-day and 1-year mortality were significantly increased.\textsuperscript{68} In all studies, the MR group had a significantly worse baseline risk profile. Nevertheless, both groups experienced a significant reduction in NYHA functional class, being in class I or II in $> 90\%$. In the PARTNER trial,\textsuperscript{49} MR at baseline was a predictor of mortality in the group with SAVR but not in the TAVI group although this observation must be interpreted with caution. Moderate MR was present in 17.4\% of patients with TAVI and 18.8\% in those undergoing SAVR.

Clinically, the most important remaining questions are:

(i) How to identify patients in whom MR will not improve after intervention remains insufficiently solved.

(ii) Whether concomitant moderate/severe MR is an independent predictor of worse outcome after intervention remains controversial.

(iii) Whether intervention on concomitant MR at the time of AVR can improve outcome remains to be shown. The fact that
additional mitral valve surgery markedly increases the risk of surgery, particularly in the elderly when significant mitral annulus calcification is present, needs to be taken into account in this context.

(iv) Whether TAVI may offer a stepwise approach with either simultaneous or later transcatheter intervention on the mitral valve (when MR remains significant) requires further investigation.

Concomitant coronary artery disease

Concomitant CAD has been reported in >60% of octogenarians undergoing SAVR and in 40 to 75% of high-risk patients undergoing TAVI. A meta-analysis of seven observational studies reported no sizeable impact of CAD on mortality in patients undergoing TAVI, but results have to be interpreted with caution due to the inclusion of heterogeneous populations, with advanced age and absence of the long-term follow-up. A detailed analysis of the impact of CAD on prognosis among patients undergoing TAVI originates from a study of 445 patients quantifying CAD using the SYNTAX score. Coronary artery disease was present in 65% of patients and categorized as a low SYNTAX score (0–22) in 47% and as high in 18%. At the 1-year follow-up, patients with a high SYNTAX score had an increased risk of cardiovascular mortality, stroke, and myocardial infarction compared with those with a low SYNTAX score or no CAD (no CAD: 13%, low SYNTAX score: 16%, high SYNTAX score: 30%; P = 0.02).

According to European Society of Cardiology/American College of Cardiology/American Heart Association (ESC/ACC/AHA) guidelines on valvular heart disease, all the patients considered for TAVI should undergo diagnostic coronary angiography as part of the routine evaluation to determine the presence and extent of CAD as well as treatment allocation (Class IC). Revascularization by percutaneous coronary intervention (PCI) among patients with severe AS undergoing TAVI has been shown feasible and safe in observational studies. In contrast to coronary artery bypass grafting (CABG) at the time of SAVR, PCI among patients undergoing TAVI appears to confer no excess short-term risk of death, myocardial infarction, and stroke compared with isolated TAVI. However, the impact of revascularization by PCI on a long-term prognosis and need for revascularization among patients undergoing TAVI is not established. The selection of lesions treated by PCI is usually based on clinical presentation and angiography since functional methods of ischaemia detection have not been validated among patients with severe AS. Some centres are comprehensive and attempt to treat any lesion with a diameter stenosis >50% whereas others limit treatment to proximal lesions with a diameter stenosis >70%. An even more conservative strategy relies on a clinical follow-up after TAVI to re-assess the

Figure 9: Mitral regurgitation improvement early and late after transcatheter aortic valve implantation. (A) Colour-Doppler transoesophageal echocardiography performed during transcatheter aortic valve implantation shows moderate mitral regurgitation in a patient with severe aortic stenosis. Immediately after transcatheter valve deployment, mitral regurgitation resolved. (B) Colour-Doppler transthoracic echocardiography showing moderate mitral regurgitation in a patient undergoing transcatheter aortic valve implantation. Periprocedural colour-Doppler transthoracic echocardiography shows unchanged moderate mitral regurgitation after valve deployment. However, at the 1-year follow-up, mitral regurgitation reduced significantly.
Figure 10  Coronary artery disease in patients undergoing transcatheter aortic valve implantation. (A) An 88-year-old man with symptomatic severe aortic stenosis (AVA 0.6 cm², mean gradient 35 mmHg) and two vessel coronary artery disease (SYNTAX Score 18) with two serial lesions in the left anterior descending coronary artery and the ostium of the first marginal branch of the left circumflex coronary artery. The STS score was 18% and a logistic EuroSCORE 53%. The patient was accepted for transcatheter aortic valve implantation and concomitant percutaneous coronary intervention. The procedure was performed sequentially. First, the serial left anterior descending coronary artery lesions were treated with a single drug-eluting stent and treatment of the ostial first marginal branch. Second, a 26 mm Edwards SAPIEN XT prosthesis was implanted. (B) An 86 year-old man with symptomatic severe aortic stenosis (AVA 0.7 cm², mean gradient 37 mmHg), normal left ventricular ejection fraction and significant coronary artery disease with a distal left main and proximal lesion of the LAD coronary artery. Risk score assessment revealed a logistic EuroSCORE of 15.9%, a STS score of 8.2%, and a SYNTAX Score of 23. The patient was accepted for transcatheter aortic valve implantation and staged percutaneous coronary intervention. First, the patient underwent successful percutaneous coronary intervention of the left main and left anterior descending coronary artery lesion by implantation of a drug-eluting stent. Second, the patient underwent transcatheter aortic valve implantation with implantation of a 29 mm Edwards SAPIEN XT prosthesis at the 6-week follow-up.
necessity of coronary intervention depending on symptoms. Of note, revascularization was less likely to be complete among patients undergoing PCI and TAVI with a high SYNTAX score (>22) compared with a low SYNTAX score. However, completeness of revascularization did not impact clinical outcomes in 124 TAVI patients with significant CAD who underwent staged or concomitant PCI in 32% of cases according to a Heart Team decision. In this context, revascularization by means of PCI is not only influenced by the complexity of underlying CAD but also by procedural considerations including the amount of contrast agent particularly among patients with renal failure, duration of the procedure, and leading clinical problem (CAD vs. AS). Another related issue is whether PCI performed during the same session as TAVI thereby limiting the number of procedures and access sites, circumstances such as complexity and duration of PCI as well as contrast agent exposure may favour a staged approach (Figure 10). Indeed, the flexibility in terms of the timing of PCI relative to the TAVI intervention should be perceived as an advantage in the overall patient management. ACTIVATION (ISRCTN75836930), a prospective trial of 310 patients with CAD and severe AS undergoing TAVI randomly assigned to PCI or medical treatment currently recruits patients and will assess the primary endpoint of all-cause mortality and re-hospitalization at 1 year. Moreover, two randomized clinical trials comparing TAVI and SAVR in intermediate-risk patients (SURTAVI: NCT01586910 and PARTNER II: NCT01314313) also include patients with significant CAD who may undergo CABG in case of SAVR or PCI in case of TAVI as advised by the Heart Team. These studies will advance our understanding of the percutaneous when compared with a surgical treatment strategy of patients with combined AS and CAD.

Conclusion

The use of TAVI in patients with severe AS who are not eligible or have high risk for SAVR has increased exponentially over the recent years. In the current article, various areas of uncertainty related to the selection of patients for TAVI were discussed. First, the current risk scores are suboptimal in identifying patients at high risk for SAVR, and improved patient selection for TAVI is needed (and should also take into account improved prediction of outcome after TAVI).

Non-invasive imaging with contemporary techniques is important in patient selection. Adequate assessment of the aortic annulus is important for prosthesis sizing, and 3D techniques such as MDCT have shown that undersizing may lead to AR after TAVI, whereas oversizing may cause annular rupture. Precise definition of valve anatomy is particularly important in bicuspid valves, which often have more extensive calcifications, and MDCT appears the technique of choice. Besides valvular anatomy, the assessment of stenosis severity can also be challenging. Not infrequent, a mismatch between the transvalvular gradient and the AVA is encountered: these patients typically have small AVA with a low gradient. In patients with LV dysfunction, low-dose dobutamine echocardiography may help to differentiate between a true (fixed) stenosis and a pseudo-stenosis (not opening of the valve) due to LV dysfunction. The mismatch between the gradient and the AVA can also be noted in patients with normal LV function, and in these patients a calcium score (derived from CT) may identify patients with a true stenosis.

It has also been recognized that LV function is important for outcome after TAVI, but prediction of reversibility of LV dysfunction after TAVI remains difficult.

Moderate-to-severe MR can be present in up to 33% of patients with severe AS treated with TAVI. Improvement in MR has been shown acutely after TAVI and may be related to the reduction in LV pressure overload; late improvement in MR after TAVI has also been reported and may be related to the LV reverse remodelling with reduction in mitral annular dimensions. Conversely, MR may also persist after TAVI. From the currently available studies, it appears that prediction of improvement is difficult. Moreover, the prognostic value of persistence of MR after TAVI is unclear.

Finally, concomitant CAD is reported in 40–75% of patients referred for TAVI, and the precise management is unclear: should revascularization be performed prior to TAVI? Different studies comparing different strategies are planned and will provide further information on this topic.

In part 2 of this review, areas of uncertainty on procedural issues and outcomes will be discussed.

Supplementary material

Supplementary material is available at European Heart Journal online.

Conflict of interest: N.P. is proctor and consultant for Medtronic, P.M. is proctor for Edwards Lifesciences, J.W. disclosed consultant fees from Edwards Lifesiences, V.D. disclosed consulting fees from Medtronic and St. Jude Medical, speaking fees from Abbott Vascular. A.P.K. is member of the steering committee of the SURTAVI trial, P.P. has research contract with Edwards Lifesciences and V-Wave Ltd., C.H. is advisor to Medtronic and received speaker fees from Abbott Vascular and Edwards Lifesciences, M.T. is advisor to Edwards Lifesciences, A.V. received speakers fees from Edwards Lifesiences, H.B. received speaker and consultant fees for Edwards Lifesiences, Direct Flow Medical, Abbott Vascular and Actelion, J.R-C. received consulting fees from Edwards Lifesiences and St. Jude Medical, V.B. is consultant for Edwards, Medtronic and St. Jude Medical. J.P.C. received research grants from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Guerbet Medical, Medtronic, Boston Scientific, Cordis, Stago, Centocor, Fondation de France, INSERM, Fédération Française de Cardiologie et Société Française de Cardiologie. The remaining authors have nothing to disclose. The Department of Cardiology of the Leiden University Medical Center received research grants from Medtronic, Boston Scientific and Biotronik. The Department of Cardiac Imaging of the University Hospital Ramon y Cajal received research grants from Philips Healthcare, Siemens and Toshiba. The Department of Cardiology of the Bern University Hospital received research grants from Biotronik and Edwards Lifesiences.

References


